Standard BioTools
LAB
134 hedge funds and large institutions have $472M invested in Standard BioTools in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 27 increasing their positions, 54 reducing their positions, and 19 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
122% more call options, than puts
Call options by funds: $9.54M | Put options by funds: $4.3M
121% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 19
89% more capital invested
Capital invested by funds: $249M → $472M (+$223M)
20% more funds holding
Funds holding: 112 → 134 (+22)
4.79% more ownership
Funds ownership: 87.97% → 92.76% (+4.8%)
50% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Atom Investors
Austin,
Texas
|
+$22.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$14.6M |
| 4 |
Millennium Management
New York
|
+$8.37M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$6.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$9.23M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$9.14M |
| 3 |
Renaissance Technologies
New York
|
-$7.99M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.53M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.99M |
LAB Hedge Fund Activity: Q3 2020 in Review
134 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2020, worth a combined $472M — up 89% from $249M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new LAB positions and 19 closed out — a net gain of 23 holders — while 27 added to existing stakes and 54 trimmed.
The largest buyer was Atom Investors, opening a new position worth an estimated $22.1M. The largest seller was Neuberger Berman Group, cutting an estimated $9.23M.
- 134 institutional investors held Standard BioTools (LAB) as of Q3 2020, up from 112 in Q2 2020.
- Funds reported $472M of Standard BioTools stock for Q3 2020, up 89% quarter-over-quarter.
- 42 funds opened new Standard BioTools positions in Q3 2020 and 19 closed out, a net change of +23 holders.
- The largest Standard BioTools buyer in Q3 2020 was Atom Investors, an estimated $22.1M added.
- The largest Standard BioTools seller in Q3 2020 was Neuberger Berman Group, an estimated $9.23M sold.
Based on aggregated 13F filings for Q3 2020.